TNF and inflammatory bowel disease: Anti-TNFα was represcribed after a median 4 months (IQR, 3–10) in 21 (66%) of 32 cases, mostly for IBD activity (16/21, 76%) after 4 months (IQR, 4–12) or to treat IRIS (5/21, 24%) with dramatic efficacity.